Lapatinib is a dual tyrosine kinase inhibitor that can inhibit the proliferation and activity of tumor cells by simultaneously acting on the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER-2). Here, ERBB2 is linked to neoplasm.